PDCD1 and neoplasm: ACT in combination with blockade of both PD-1 and CTLA-4 has shown particularly good effects (41), most likely because the anti-PD-1 treatment counteracts PD-L1-mediated inactivation of T cells whereas anti-CTLA-4 enhances priming of endogenous tumor-reactive T cells (42, 43).